Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Dow Jones

昨天

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. $(TNGX)$, today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:

Elizabeth Hickin

IR@tangotx.com

media@tangotx.com

(END) Dow Jones Newswires

May 01, 2025 07:00 ET (11:00 GMT)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532168078"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532168078\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532168078?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532168078","market":"nz","top_or_hot":-1,"title":"Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 \n</p>\n<p>\n     BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. <a href=\"https://laohu8.com/S/TNGX\">$(TNGX)$</a>, today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. \n</p>\n<p>\n     About Tango Therapeutics \n</p>\n<p>\n     Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. \n</p>\n<p>\n     Investors and Media: \n</p>\n<p>\n     Elizabeth Hickin \n</p>\n<p>\n     IR@tangotx.com \n</p>\n<p>\n     media@tangotx.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2025 07:00 ET (11:00 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-05-01 19:00</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 \n</p>\n<p>\n     BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. <a href=\"https://laohu8.com/S/TNGX\">$(TNGX)$</a>, today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. \n</p>\n<p>\n     About Tango Therapeutics \n</p>\n<p>\n     Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. \n</p>\n<p>\n     Investors and Media: \n</p>\n<p>\n     Elizabeth Hickin \n</p>\n<p>\n     IR@tangotx.com \n</p>\n<p>\n     media@tangotx.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2025 07:00 ET (11:00 GMT)\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2532168078","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532168078","pubTimestamp":1746097200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BOSTON, May 01, 2025  -- Tango Therapeutics, Inc. , today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","TNGX":"Tango Therapeutics Inc."},"translate_title":"新闻稿：Tango Therapeutics将于2025年5月12日星期一报告2025年第一季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TNGX":0.9},"content_text":"Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 \n\n\n     BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. $(TNGX)$, today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. \n\n\n     About Tango Therapeutics \n\n\n     Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. \n\n\n     Investors and Media: \n\n\n     Elizabeth Hickin \n\n\n     IR@tangotx.com \n\n\n     media@tangotx.com \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2025 07:00 ET (11:00 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}